VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a.
Vincerx Pharma, Inc. (NASDAQ:VINC – Get Free Report) was the target of a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 123,200 shares, a drop of 20.1% from the November 30th total of 154,200 shares. Approximately 0.9% of the shares of the company are […]
Cantor Fitzgerald reissued their overweight rating on shares of Vincerx Pharma (NASDAQ:VINC – Free Report) in a research note published on Thursday, Benzinga reports. They currently have a $5.00 price target on the stock. Vincerx Pharma Stock Performance VINC opened at $0.71 on Thursday. Vincerx Pharma has a fifty-two week low of $0.63 and a […]
Vincerx Pharma, Inc. (NASDAQ:VINC – Free Report) – Analysts at Leerink Partnrs lifted their Q3 2023 earnings per share (EPS) estimates for Vincerx Pharma in a research report issued on Monday, August 7th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings of ($0.49) per share for the quarter, up from […]